$DYN SEC Filings

Filed On	Filing
22 Oct 2026	Form 4: Kerr Douglas, Head of R&D and CMO Received 8,000 shares as a grant or award · Granted 12,000 Stock option (right to buy)
06 Oct 2026	Form 4: Posner Brian S, Director Bought 2,500 shares ($40K)
29 Sep 2026	8-K: Regulation FD Disclosure; Other Events Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
08 Sep 2026	144
08 Sep 2026	144
08 Sep 2026	Form 4: Friedl-Naderer Johanna, Chief Commercial Officer Sold 900 shares ($21.9K) · Sold 185 shares ($3.49K)
08 Sep 2026	Form 4: Kerr Douglas, Chief Medical Officer Sold 3,745 shares ($91.2K) · Sold 1,290 shares ($24.4K)
08 Sep 2026	Form 4: Cox John, Director Sold 5,658 shares ($107K)
04 Sep 2026	144
17 Aug 2026	Form 4: Rhodes Jason P, Director Sold 426,412 shares ($11.2M) · Sold 2,160,516 shares ($54M)
17 Aug 2026	Form 4: Friedl-Naderer Johanna, Chief Commercial Officer Sold 226 shares ($5.94K)
17 Aug 2026	Form 4: Kerr Douglas, Chief Medical Officer Sold 1,556 shares ($40.9K)
17 Aug 2026	Form 4: Cox John, Director Sold 4,986 shares ($131K)
17 Aug 2026	Form 4: Lucera Erick, Chief Financial Officer Sold 1,797 shares ($47.2K)
14 Aug 2026	144
14 Aug 2026	144
14 Aug 2026	144
13 Aug 2026	144
13 Aug 2026	144
13 Aug 2026	144

Comments